This compounded product should only be used for an approved medical purpose under close medical supervision, with follow-up lab testing as directed.
Cagrilintide monotherapy may be a good fit if: You have tried GLP-1 receptor agonists and could not tolerate the vomiting You prefer a compound with a very low treatment discontinuation rate You are comfortable with elevated injection site reactions Your weight loss target is moderate (10-15% body weight) You want to try a novel mechanism of action (amylin vs GLP-1) CagriSema may be worth considering if: You need more aggressive weight loss (15-20%+) You tolerated GLP-1 receptor agonists reasonably well You can manage more significant GI side effects The additional weight loss justifies the additional side effect burden for your situation You should consider alternatives if: Injection site reactions are a major concern for you You have history of pancreatitis or severe GI conditions You have personal or family history of medullary thyroid carcinoma You need an FDA-approved option with extensive post-marketing safety data Fatigue would significantly impact your work or training Our best peptides for weight loss guide and best fat burning peptide comparison can help researchers who determine that cagrilintide is not the right fit explore other options
Each capsule contains a standardized dose of BPC-157 (typically 500 mcg)
Without adequate blood supply, healing stalls regardless of other favorable conditions
The other exists primarily in clinical trials and research supply chains
The single human musculoskeletal paper that gets cited often is a small retrospective case series of intra-articular BPC-157 injections for multiple types of knee pain. It reported improvement in 11 of 12 patients, but the study has major limitations: no control group, no standardized objective outcome measures, no imaging confirmation of pathology, and unclear diagnostic specificity
